Cart
sales@molnova.com
Cimiracemoside C
CAS No. 256925-92-5
Cimiracemoside C( Cimicifugoside M )
Catalog No. M24157 CAS No. 256925-92-5
Cimiracemoside C is an active component of Cimicifuga racemosa. It activates AMPK and has the potential activity against diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 149 | In Stock |
|
| 10MG | 255 | In Stock |
|
| 25MG | 430 | In Stock |
|
| 50MG | 618 | In Stock |
|
| 100MG | 861 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCimiracemoside C
-
NoteResearch use only, not for human use.
-
Brief DescriptionCimiracemoside C is an active component of Cimicifuga racemosa. It activates AMPK and has the potential activity against diabetes.
-
DescriptionCimiracemoside C is an active component of Cimicifuga racemosa. It activates AMPK and has the potential activity against diabetes.
-
In Vitro——
-
In Vivo——
-
SynonymsCimicifugoside M
-
PathwayMembrane Transporter/Ion Channel
-
TargetAMPK
-
RecptorAMPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number256925-92-5
-
Formula Weight620.8
-
Molecular FormulaC35H56O9
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC[C@]12[C@@]3([H])[C@@]4(CC[C@@]1([C@]5([H])C(O[C@H](C(C)(O)C)[C@@]6([H])C[C@H]5C)(O6)[C@@H]2O)C)[C@@]7([C@@](C(C)([C@@H](O[C@@]8([H])[C@@H]([C@H]([C@@H](O)CO8)O)O)CC7)C)([H])CC3)C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice.Phytomedicine. 2014 Sep 25;21(11):1382-9.
molnova catalog
related products
-
MK-3903
MK-3903 is a potent and selective, direct and oral AMPK activator with EC50 of 9 nM.
-
ASP4132
ASP4132 is an orally active AMPK activator (EC50 : 18 nM), has anti-cancer activity.
-
Onjisaponin B
Onjisaponin B induces autophagy via the AMPK-mTOR signaling pathway, increases the NGF level and accelerates both the removal of mutant huntingtin and A53T α±-synuclein, it may have potential therapeutic effects on Parkinson disease, Alzheimer disease and Huntington disease.
